Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa

Neuropharmacology

Volumn 48, Issue 3, 2005, Pages 398-405

  Togasaki, Daniel M ^a   Protell, Peter ^a   Tan, Louis C S ^a   William Langston, J ^a   Di Monte, Donato A ^a   Quik, Maryka ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

Dopamine; Dyskinesia; Levodopa; Monkey; Nomifensine; Parkinson

Indexed keywords

LEVODOPA; NOMIFENSINE;

ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG SELECTIVITY; DYSKINESIA; MONKEY; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL;

EID: 13844266039     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.10.009     Document Type: Article

References (40)

1. S.M. Aquilonius, K. Bergstrom, S.A. Eckernas, P. Hartvig, K.L. Leenders, H. Lundquist, G. Antoni, A. Gee, A. Rimland, and J. Uhlin In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography Acta Neurol. Scand. 76 1987 283 287
2. P.J. Bedard, P.J. Blanchet, D. Levesque, J.J. Soghomonian, R. Grondin, M. Morissette, M. Goulet, F. Calon, P. Falardeau, B. Gomez-Mancilla, J.P. Doucet, G.S. Robertson, and T. DiPaolo Pathophysiology of l-dopa-induced dyskinesias Mov. Disord. 14 Suppl. 1 1999 4 8
3. M.P. Caligiuri, and S. Peterson A quantitative study of levodopa-induced dyskinesia in Parkinson's disease J. Neural Transm. Park. Dis. Dement. Sect. 6 1993 89 98
4. F. Calon, R. Grondin, M. Morissette, M. Goulet, P.J. Blanchet, T. Di Paolo, and P.J. Bedard Molecular basis of levodopa-induced dyskinesias Ann. Neurol. 47 2000 S70 S78
5. J.M. Cedarbaum, M. Silvestri, and H. Kutt Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements Neurology 40 1990 995 997
6. T.N. Chase The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease Drugs 55 Suppl. 1 1998 1 9
7. T.N. Chase, J.D. Oh, and P.J. Blanchet Neostriatal mechanisms in Parkinson's disease Neurology 51 1998 S30 S35
8. W.J. Conover Practical Nonparametric Statistics 1999 John Wiley New York pp. 419-420
9. M. Daras, B.S. Koppel, and E. Atos-Radzion Cocaine-induced choreoathetoid movements ('crack dancing') Neurology 44 1994 751 752
10. D.A. Di Monte, A. McCormack, G. Petzinger, A.M. Janson, M. Quik, and W.J. Langston Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model Mov. Disord. 15 2000 459 466
11. S. Fahn The spectrum of levodopa-induced dyskinesias Ann. Neurol. 47 2000 S2 S9 discussion S9-S11
12. A.C. Gibson Nomifensine and dyskinesia Br. J. Psychiatry 138 1981 439
13. B. Giros, M. Jaber, S.R. Jones, R.M. Wightman, and M.G. Caron Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter Nature 379 1996 606 612
14. R. Habal, D. Sauter, O. Olowe, and M. Daras Cocaine and chorea Am. J. Emerg. Med. 9 1991 618 620
15. M.J. Hansard, L.A. Smith, M.J. Jackson, S.C. Cheetham, and P. Jenner The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates Mov. Disord. 19 2004 15 21
16. M. Jaber, S. Jones, B. Giros, and M.G. Caron The dopamine transporter: a crucial component regulating dopamine transmission Mov. Disord. 12 1997 629 633
17. P. Jenner Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation Neurology 62 2004 S47 S55
18. S.R. Jones, R.R. Gainetdinov, M. Jaber, B. Giros, R.M. Wightman, and M.G. Caron Profound neuronal plasticity in response to inactivation of the dopamine transporter Proc. Natl Acad. Sci. U.S.A. 95 1998 4029 4034
19. E. Koritar Nomifensine-induced dyskinesia Can. Med. Assoc. J. 133 1985 207
20. J.W. Langston, E.B. Langston, and I. Irwin MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects Acta Neurol. Scand. Suppl. 100 1984 49 54
21. S.R. Letchworth, M.A. Nader, H.R. Smith, D.P. Friedman, and L.J. Porrino Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys J. Neurosci. 21 2001 2799 2807
22. R.J. Mones, T.S. Elizan, and G.J. Siegel Analysis of l-dopa induced dyskinesias in 51 patients with Parkinsonism J. Neurol. Neurosurg. Psychiatry 34 1971 668 673
23. J.G. Nutt Levodopa-induced dyskinesia: review, observations, and speculations Neurology 40 1990 340 345
24. J.G. Nutt, J.A. Obeso, and F. Stocchi Continuous dopamine-receptor stimulation in advanced Parkinson's disease Trends Neurosci. 23 2000 S109 S115
25. J.A. Obeso, M. Rodriguez-Oroz, C. Marin, F. Alonso, I. Zamarbide, J.L. Lanciego, and M. Rodriguez-Diaz The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits Neurology 62 2004 S17 S30
26. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodriguez, M.R. DeLong, and C.W. Olanow Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model Ann. Neurol. 47 2000 S22 S32 discussion S32-S34
27. M. Onofrj, C. Paci, and A. Thomas Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease J. Neurol. Neurosurg. Psychiatry 65 1998 605 606
28. D.M. Park, L.J. Findley, G. Hanks, and M. Sandler Nomifensine: effect in Parkinsonian patients not receiving levodopa J. Neurol. Neurosurg. Psychiatry 44 1981 352 354
29. D.M. Park, L.J. Findley, and P.F. Teychenne Nomifensine in parkinsonism Br. J. Clin. Pharmacol. 4 Suppl. 2 1977 185S 186S
30. R.K. Pearce, M. Heikkila, I.B. Linden, and P. Jenner l-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations Psychopharmacology (Berl) 156 2001 402 409
31. R.K. Pearce, L.A. Smith, M.J. Jackson, T. Banerji, J. Scheel-Kruger, and P. Jenner The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets Mov. Disord. 17 2002 877 886
32. P.H. Protell, D.M. Togasaki, L. Tan, J.W. Langston, D.A. Di Monte, and M. Quik Blockade of dopamine reuptake enhances levodopa-induced dyskinesias Soc. Neurosci. Abstr. 27 2001 514.515
33. R. Sandyk Nomifensine in advanced parkinsonism Clin. Neuropharmacol. 8 1985 296 297
34. R. Sandyk Nomifensine-induced orofacial dyskinesia and Sydenham's chorea Int. J. Neurosci. 35 1987 91 92
35. R. Sandyk, and M.A. Gillman Nomifensine exacerbates orofacial dyskinesia in hypothyroidism Neurology 35 1985 282
36. F. Stocchi, and C.W. Olanow Continuous dopaminergic stimulation in early and advanced Parkinson's disease Neurology 62 2004 S56 S63
37. L.C. Tan, P.H. Protell, J.W. Langston, and D.M. Togasaki The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys Mov. Disord. 17 2002 902 909
38. D.M. Togasaki, L. Tan, P. Protell, D.A. Di Monte, M. Quik, and J.W. Langston Levodopa induces dyskinesias in normal squirrel monkeys Ann. Neurol. 50 2001 254 257
39. D.M. Togasaki, P.H. Protell, L.C.S. Tan, J.W. Langston, D.A. Di Monte, and M. Quik Tolerance to nomifensine-induced dyskinesias in normal squirrel monkeys Soc. Neurosci. Abstr. 30 2004 563.9
40. N.R. Zahniser, G.A. Larson, and G.A. Gerhardt In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors J. Pharmacol. Exp. Ther. 289 1999 266 277